International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman diseaseFrits van Rhee, David C. Fajgenbaum, Makoto Ide et al.|Blood|2018Cited by 421
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare DisorderSheila K. Pierson, David C. Fajgenbaum, Johnson S. Khor et al.|Cell Reports Medicine|2020Cited by 33
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C. Fajgenbaum, David Wu, Aaron M. Goodman et al.|American Journal of Hematology|2020Cited by 32